Sana Biotechnology (NASDAQ:SANA) Announces Earnings Results, Beats Expectations By $0.01 EPS

Sana Biotechnology (NASDAQ:SANA) posted its quarterly earnings data on Friday. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01, Zacks reports.

Sana Biotechnology Stock Down 3.8 %

NASDAQ:SANA traded down $0.11 during midday trading on Monday, hitting $2.89. The stock had a trading volume of 1,981,002 shares, compared to its average volume of 2,151,145. The stock has a 50-day moving average of $4.21 and a 200 day moving average of $5.77. The company has a market capitalization of $642.93 million, a price-to-earnings ratio of -2.29 and a beta of 1.44. Sana Biotechnology has a one year low of $2.76 and a one year high of $12.00.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. JMP Securities downgraded shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Sana Biotechnology in a research note on Monday. Finally, Citigroup upped their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, August 9th.

Insiders Place Their Bets

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the sale, the director now owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 31.10% of the stock is owned by company insiders.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.